Journal
VACCINE
Volume 28, Issue 14, Pages 2593-2597Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.01.018
Keywords
Pulmonary vaccination; ISCOMATRIX (TM) adjuvant; Recombinant antigens
Categories
Funding
- Australian Research Council [LP0347058]
- CSL Limited
- Australian Research Council [LP0347058] Funding Source: Australian Research Council
Ask authors/readers for more resources
Deep pulmonary delivery of an influenza ISCOMATRIX (TM) vaccine has previously been shown to induce a combined mucosal and systemic antibody response. To explore whether this combined response is influenced by intrinsic properties of the component antigen, we examined the efficacy of deep pulmonary delivery of ISCOMATRIX (TM) vaccines containing different recombinant antigens, specifically gB glycoprotein from cytomegalovirus and a fragment of catalase from Helicobacter pylori. Both these vaccines induced antigen-specific mucosal and systemic immunity, as well as antigen-specific proliferative cellular responses. Pulmonary immunisation with ISCOMATRIX (TM) vaccines may therefore be a generic way of inducing combined systemic and mucosal immunity. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available